Guidance on labelling requirements pertinent to the type of medicinal product and its supply status, as defined in UK legislation.
Similar Posts
100 years of protecting patients through biological standards for medicines
The MHRA produces over 95 per cent of the World Health Organization’s (WHO) biological standards.
UK sets out world‑leading pathway for space‑manufactured drugs
Patients could benefit from more effective, higher quality and longer lasting medicines as the UK sets out a clearer route to bring drugs manufactured in space safely to market.
M6-C Artificial Cervical Disc, Spinal Kinetics LLC: New monitoring requirements for the risk of osteolysis
The MHRA has conducted an assessment following reports of osteolysis and early device failure in the literature and is issuing new monitoring requirements for patients implanted with the M6-C artificial cervical disc.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
Variations to marketing authorisations (MAs)
How the MHRA processes variations to marketing authorisations.
Decision: Human and veterinary medicines: register of licensed manufacturing sites
The MHRA register of licensed manufacturing sites: manufacturer specials – human (MS) and manufacturer specials authorisation – veterinary (MANSA) only.